"Nootropic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs used to specifically facilitate learning or memory, particularly to prevent the cognitive deficits associated with dementias. These drugs act by a variety of mechanisms. While no potent nootropic drugs have yet been accepted for general use, several are being actively investigated.
Descriptor ID |
D018697
|
MeSH Number(s) |
D27.505.954.427.637
|
Concept/Terms |
Nootropic Agents- Nootropic Agents
- Agents, Nootropic
- Nootropics
- Cognitive Enhancers
- Enhancers, Cognitive
- Nootropic Drugs
- Drugs, Nootropic
|
Below are MeSH descriptors whose meaning is more general than "Nootropic Agents".
Below are MeSH descriptors whose meaning is more specific than "Nootropic Agents".
This graph shows the total number of publications written about "Nootropic Agents" by people in this website by year, and whether "Nootropic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2001 | 0 | 1 | 1 |
2006 | 0 | 1 | 1 |
2007 | 1 | 0 | 1 |
2012 | 1 | 0 | 1 |
2013 | 1 | 0 | 1 |
2015 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Nootropic Agents" by people in Profiles.
-
Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, Jacobs AH, Wyss-Coray T, Vitorica J, Ransohoff RM, Herrup K, Frautschy SA, Finsen B, Brown GC, Verkhratsky A, Yamanaka K, Koistinaho J, Latz E, Halle A, Petzold GC, Town T, Morgan D, Shinohara ML, Perry VH, Holmes C, Bazan NG, Brooks DJ, Hunot S, Joseph B, Deigendesch N, Garaschuk O, Boddeke E, Dinarello CA, Breitner JC, Cole GM, Golenbock DT, Kummer MP. Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015 Apr; 14(4):388-405.
-
Bowen RL, Perry G, Xiong C, Smith MA, Atwood CS. A clinical study of lupron depot in the treatment of women with Alzheimer's disease: preservation of cognitive function in patients taking an acetylcholinesterase inhibitor and treated with high dose lupron over 48 weeks. J Alzheimers Dis. 2015; 44(2):549-60.
-
Bharadwaj PR, Bates KA, Porter T, Teimouri E, Perry G, Steele JW, Gandy S, Groth D, Martins RN, Verdile G. Latrepirdine: molecular mechanisms underlying potential therapeutic roles in Alzheimer's and other neurodegenerative diseases. Transl Psychiatry. 2013 Dec 03; 3:e332.
-
Harms JE, Benveniste M, Maclean JK, Partin KM, Jamieson C. Functional analysis of a novel positive allosteric modulator of AMPA receptors derived from a structure-based drug design strategy. Neuropharmacology. 2013 Jan; 64:45-52.
-
Devan BD, Pistell PJ, Daffin LW, Nelson CM, Duffy KB, Bowker JL, Bharati IS, Sierra-Mercado D, Spangler EL, Ingram DK. Sildenafil citrate attenuates a complex maze impairment induced by intracerebroventricular infusion of the NOS inhibitor Nomega-nitro-L-arginine methyl ester. Eur J Pharmacol. 2007 Jun 01; 563(1-3):134-40.
-
Moreira PI, Honda K, Zhu X, Nunomura A, Casadesus G, Smith MA, Perry G. Brain and brawn: parallels in oxidative strength. Neurology. 2006 Jan 24; 66(2 Suppl 1):S97-101.
-
Paul R, Cohen R, Moser D, Ott B, Zawacki T, Gordon N. Performance on the Hooper Visual Organizational Test in patients diagnosed with subcortical vascular dementia: relation to naming performance. Neuropsychiatry Neuropsychol Behav Neurol. 2001 Apr-Jun; 14(2):93-7.